Pfizer announced over the weekend that it would be backing out of research and development into the neuroscience area, abandoning a number of Phase 1 and 2 projects and removing a number of positions from the company.
Ook interessant voor je
Pfizer announced over the weekend that it would be backing out of research and development into the neuroscience area, abandoning a number of Phase 1 and 2 projects and removing a number of positions from the company.
Pharmamarketeer richt zich op marketingprofessionals van farmaceuten en andere medisch-gerelateerde organisaties in Nederland en België.
Copyright 2023 © Uitgave van MedHealth Communications BV | Privacy disclaimer
Reageer